Cardinal Health (NYSE:CAH) Price Target Raised to $139.00

Cardinal Health (NYSE:CAH) had its price target hoisted by stock analysts at UBS Group from $134.00 to $139.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price would suggest a potential upside of 22.81% from the company’s current price.

Several other equities analysts also recently commented on the company. Barclays increased their target price on Cardinal Health from $117.00 to $133.00 and gave the company an “overweight” rating in a research report on Monday. Evercore ISI increased their price target on Cardinal Health from $105.00 to $115.00 and gave the company an “in-line” rating in a research note on Thursday, August 15th. Wells Fargo & Company increased their price target on Cardinal Health from $95.00 to $101.00 and gave the company an “underweight” rating in a research note on Thursday, August 15th. Robert W. Baird increased their price target on Cardinal Health from $130.00 to $137.00 and gave the company an “outperform” rating in a research note on Thursday, August 15th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Cardinal Health from $115.00 to $119.00 and gave the company a “hold” rating in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Cardinal Health has a consensus rating of “Moderate Buy” and an average price target of $123.00.

Cardinal Health Trading Up 1.1 %

Cardinal Health stock opened at $113.18 on Monday. The company has a market capitalization of $27.39 billion, a PE ratio of 22.02, a P/E/G ratio of 1.57 and a beta of 0.60. Cardinal Health has a 12 month low of $93.17 and a 12 month high of $119.13. The stock has a 50-day moving average price of $111.79 and a two-hundred day moving average price of $104.20.

Cardinal Health (NYSE:CAH) last posted its earnings results on Friday, November 1st. The company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The firm had revenue of $52.28 billion during the quarter, compared to the consensus estimate of $50.90 billion. Cardinal Health had a negative return on equity of 56.56% and a net margin of 0.56%. The business’s quarterly revenue was down 4.3% on a year-over-year basis. During the same period last year, the company earned $1.73 earnings per share. As a group, analysts predict that Cardinal Health will post 7.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jessica L. Mayer sold 16,573 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $109.39, for a total transaction of $1,812,920.47. Following the completion of the sale, the insider now owns 75,971 shares of the company’s stock, valued at $8,310,467.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Cardinal Health news, insider Jessica L. Mayer sold 16,573 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $109.39, for a total value of $1,812,920.47. Following the completion of the sale, the insider now owns 75,971 shares of the company’s stock, valued at approximately $8,310,467.69. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jessica L. Mayer sold 17,896 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $106.48, for a total value of $1,905,566.08. Following the completion of the sale, the insider now directly owns 94,529 shares of the company’s stock, valued at $10,065,447.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,963 shares of company stock valued at $12,379,980 over the last 90 days. Company insiders own 0.09% of the company’s stock.

Institutional Investors Weigh In On Cardinal Health

A number of hedge funds have recently added to or reduced their stakes in CAH. Eastern Bank bought a new position in shares of Cardinal Health in the third quarter valued at approximately $25,000. Cultivar Capital Inc. bought a new position in shares of Cardinal Health in the second quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Cardinal Health in the second quarter valued at approximately $29,000. Hara Capital LLC bought a new position in shares of Cardinal Health in the third quarter valued at approximately $31,000. Finally, LRI Investments LLC bought a new position in shares of Cardinal Health in the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.